108 related articles for article (PubMed ID: 499312)
1. Dissociation of biochemical and hypotensive effects of debrisoquine in hypertensive patients.
Silas JH; Jones J; Tucker GT; Townshend MM; Phillips CA; Smith AJ
Eur J Clin Pharmacol; 1979 Sep; 16(2):81-6. PubMed ID: 499312
[TBL] [Abstract][Full Text] [Related]
2. Why hypertensive patients vary in their response to oral debrisoquine.
Silas JH; Lennard MS; Tucker GT; Smith AJ; Malcolm SL; Marten TR
Br Med J; 1977 Feb; 1(6058):422-5. PubMed ID: 837136
[TBL] [Abstract][Full Text] [Related]
3. Interrelations among blood pressure, blood volume, plasma renin activity and urinary catecholamines in benign essential hypertension.
Weidmann P; Hirsch D; Beretta-Piccoli C; Reubi FC; Ziegler WH
Am J Med; 1977 Feb; 62(2):209-18. PubMed ID: 835600
[TBL] [Abstract][Full Text] [Related]
4. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism?
Eisenhofer G; Friberg P; Pacak K; Goldstein DS; Murphy DL; Tsigos C; Quyyumi AA; Brunner HG; Lenders JW
Clin Sci (Lond); 1995 May; 88(5):533-42. PubMed ID: 7614812
[TBL] [Abstract][Full Text] [Related]
5. Interrelations between age and plasma renin, aldosterone and cortisol, urinary catecholamines, and the body sodium/volume state in normal man.
Weidmann P; de Chatel R; Schiffmann A; Bachmann E; Beretta-Piccoli C; Reubi FC; Ziegler WH; Vetter W
Klin Wochenschr; 1977 Aug; 55(15):725-33. PubMed ID: 895008
[TBL] [Abstract][Full Text] [Related]
6. Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats.
Bryan-Lluka LJ; Seers H; Sharpe I
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):536-44. PubMed ID: 8740147
[TBL] [Abstract][Full Text] [Related]
7. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
[TBL] [Abstract][Full Text] [Related]
8. Platelet and plasma amine oxidase inhibition and urinary amine excretion changes during phenelzine treatment.
Murphy DL; Brand E; Goldman T; Baker M; Wright C; van Kammen D; Gordon E
J Nerv Ment Dis; 1977 Feb; 164(2):129-34. PubMed ID: 836485
[TBL] [Abstract][Full Text] [Related]
9. Relationship between plasma renin activity and urinary catecholamines in various types of hypertension.
Horký K; Kopecká J; Greogorová I; Dvoráková J
Endokrinologie; 1976 Jul; 67(3):331-42. PubMed ID: 976208
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular counterregulation during sympathetic inhibition in normal subjects and patients with mild hypertension.
Weidmann P; Beretta-Piccoli C; Link L; Bianchetti MG; Boehringer K; Morton JJ
Hypertension; 1983; 5(6):873-80. PubMed ID: 6360870
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials with Tendor (debrisoquine sulfate).
Langer L; Gerö A
Ther Hung; 1974; 22(4):165-71. PubMed ID: 4465961
[No Abstract] [Full Text] [Related]
12. The effects of guanethidine, bretylium and debrisoquine on the accumulation of noradrenaline in constricted postganglionic sympathetic nerves in vitro.
Tomlinson DR; Mayor D
Eur J Pharmacol; 1973 Feb; 21(2):161-70. PubMed ID: 4696099
[No Abstract] [Full Text] [Related]
13. Concentration of debrisoquine by human platelets in vivo: relationship to hypotensive effect [proceedings].
Lennard MS; Silas JH; Smith AJ; Tucker GT
Br J Clin Pharmacol; 1977 Oct; 4(5):635P. PubMed ID: 911620
[No Abstract] [Full Text] [Related]
14. [Correlations between blood pressure, blood volume, plasma renin and urinary catecholamines in normal subjects and in patients with benign essential hypertension].
Weidmann P; Hirsch D; Beretta-Piccoli C; Reubi FC; Ziegler WH
Schweiz Med Wochenschr; 1976 Dec; 106(49):1741-3. PubMed ID: 1013697
[TBL] [Abstract][Full Text] [Related]
15. Effects of debrisoquin on the excretion of catecholamine and octopamine metabolites in the rat and guinea pig.
Edwards DJ; Ravitch J; Knopf S
Biochem Pharmacol; 1985 Aug; 34(16):2911-6. PubMed ID: 3896245
[TBL] [Abstract][Full Text] [Related]
16. Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs.
Lennard MS; Crewe HK; Tucker GT; Woods HF
Biochem Pharmacol; 1986 Aug; 35(16):2757-61. PubMed ID: 2943287
[TBL] [Abstract][Full Text] [Related]
17. [Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension (author's transl)].
Weidmann P; Beretta-Piccoli C; Ziegler W; Hirsch D; de Châtel RD; Reubi FC
Klin Wochenschr; 1976 Aug; 54(16):765-73. PubMed ID: 8663
[TBL] [Abstract][Full Text] [Related]
18. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
19. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
20. Timolol metabolism and debrisoquine oxidation polymorphism: a population study.
Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF
Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
